NCI-H1793 Cells

NCI-H1793 is a human non-small cell lung cancer (NSCLC) cell line derived from an adult patient with lung adenocarcinoma. The cells exhibit epithelial morphology and grow adherently in standard tissue culture conditions. As a representative model of pulmonary adenocarcinoma, NCI-H1793 retains key molecular and phenotypic characteristics associated with this histological subtype, making it suitable for in vitro studies of lung cancer biology, tumor progression, and therapeutic response.

Molecular characterization of NCI-H1793 has identified an activating mutation in the KRAS oncogene (G12C), a common driver alteration in lung adenocarcinoma. This mutation results in constitutive activation of downstream signaling pathways, including the MAPK and PI3K-AKT cascades, promoting proliferation and survival. The presence of KRAS G12C makes NCI-H1793 particularly valuable for investigating RAS-driven oncogenic signaling and for evaluating targeted inhibitors directed against mutant KRAS or its downstream effectors. The cell line has also been reported to harbor additional genomic alterations typical of NSCLC, supporting its relevance as a preclinical model for molecularly defined lung cancer.

Due to its defined oncogenic background and epithelial tumor phenotype, NCI-H1793 is widely used in studies assessing targeted therapies, resistance mechanisms, and combination treatment strategies in KRAS-mutant lung cancer. It serves as a robust platform for functional genomics, drug screening, and pathway analysis aimed at elucidating vulnerabilities in RAS-driven malignancies.